Merck releases KEYNOTE-013 KEYTRUDA data

The data showed KEYTRUDA demonstrated an ORR of 41 percent. | File image

Merck recently released KEYTRUDA data demonstrating an overall response rate of 41 percent in patients with relapsed or refractory primary mediastinal large B-cell lymphoma.

The results, which are from the KEYNOTE-013 trial, included a follow-up of up to 27 months.

“For patients with primary mediastinal large B-cell lymphoma who are ineligible for, or fail to respond to, autologous stem-cell transplantation, the prognosis is very poor and there are limited treatment options,” University of Bologna Associate Professor of Hematology Dr. Pier Luigi Zinzani said. “Based on the rarity of this type of blood cancer, clinical research has been historically limited, and it’s encouraging to see clinical trials conducted in this disease where we are seeing durable responses with KEYTRUDA.”

In KEYTRUDA-treated patients, 86 percent of responses at the time of analyses were ongoing with the median duration not reached.

“We are committed to studying immuno-oncology approaches across a broad spectrum of cancers, including studies in more than 20 hematological subtypes,” Merck Research Laboratories Senior Vice President Dr. Roger Dansey said. “These data continue to support the efficacy and safety profile of KEYTRUDA in primary mediastinal large B-cell lymphoma and the importance of ongoing evaluation in this patient population.”

Want to get notified whenever we write about Merck ?
Next time we write about Merck, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Merck 2000 Galloping Hill Rd Kenilworth, NJ 07033